Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses.
Crohn’s disease
matrix metalloproteinases
membrane-bound and soluble PD-L1
myo-/fibroblasts
Journal
International immunology
ISSN: 1460-2377
Titre abrégé: Int Immunol
Pays: England
ID NLM: 8916182
Informations de publication
Date de publication:
09 01 2020
09 01 2020
Historique:
received:
28
11
2018
accepted:
30
09
2019
pubmed:
22
10
2019
medline:
3
6
2020
entrez:
22
10
2019
Statut:
ppublish
Résumé
Increased T helper (Th)1/Th17 immune responses are a hallmark of Crohn's disease (CD) immunopathogenesis. CD90+ (myo-)fibroblasts (MFs) are abundant cells in the normal (N) intestinal mucosa contributing to mucosal tolerance via suppression of Th1 cell activity through cell surface membrane-bound PD-L1 (mPD-L1). CD-MFs have a decreased level of mPD-L1. Consequently, mPD-L1-mediated suppression of Th1 cells by CD-MFs is decreased, yet the mechanism responsible for the reduction in mPDL-1 is unknown. Increased expression of matrix metalloproteinases (MMPs) has been reported in CD. Herein we observed that when compared to N- and ulcerative colitis (UC)-MFs, CD-MFs increase in LPS-inducible levels of MMP-7 and -9 with a significant increase in both basal and inducible MMP-10. A similar pattern of MMP expression was observed in the CD-inflamed mucosa. Treatment of N-MFs with a combination of recombinant human MMP-7, -9 and -10 significantly decreased mPD-L1. In contrast, inhibition of MMP activity with MMP inhibitors or anti-MMP-10 neutralizing antibodies restores mPD-L1 on CD-MFs. CD-MFs demonstrated reduced capacity to suppress Th1 and Th17 responses from activated CD4+ T cells. By contrast, supplementation of the CD-MF:T-cell co-cultures with MMP inhibitors or anti-MMP neutralizing antibodies restored the CD-MF-mediated suppression. Our data suggest that (i) increased MMP-10 expression by CD-MFs and concomitant cleavage of PD-L1 from the surface of CD-MFs are likely to be one of the factors contributing to the decrease of mPD-L1-mediated suppression of Th1/Th17 cells in CD; and (ii) MMPs are likely to have a significant role in the intestinal mucosal immune responses.
Identifiants
pubmed: 31633754
pii: 5601595
doi: 10.1093/intimm/dxz060
pmc: PMC7185192
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Thy-1 Antigens
0
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-68Subventions
Organisme : NCI NIH HHS
ID : R01 CA207051
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103150
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001440
Pays : United States
Informations de copyright
© The Japanese Society for Immunology. 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Front Immunol. 2013 Sep 30;4:307
pubmed: 24137162
Oncogene. 2003 Nov 27;22(54):8662-70
pubmed: 14647460
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Oncoimmunology. 2015 Oct 29;5(3):e1091146
pubmed: 27141350
Histopathology. 2001 Jul;39(1):50-9
pubmed: 11454044
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Sci Rep. 2016 May 26;6:26747
pubmed: 27226337
Infect Immun. 2000 Dec;68(12):7010-7
pubmed: 11083826
Int J Oncol. 2018 Feb;52(2):379-388
pubmed: 29345283
Mol Cell Biochem. 2003 Nov;253(1-2):269-85
pubmed: 14619979
Front Immunol. 2019 Jun 14;10:1337
pubmed: 31258527
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
Inflamm Bowel Dis. 2012 Jan;18(1):120-30
pubmed: 21438097
Front Immunol. 2018 May 30;9:1125
pubmed: 29910803
Immunobiology. 2016 Sep;221(9):927-33
pubmed: 27290609
J Crohns Colitis. 2014 Oct;8(10):1147-65
pubmed: 24731838
J Immunol. 1996 Aug 1;157(3):1261-70
pubmed: 8757634
J Immunol. 2013 Oct 1;191(7):3838-46
pubmed: 23997227
Eur J Clin Invest. 2017 Feb;47(2):109-116
pubmed: 27714784
Eur J Biochem. 1998 Apr 1;253(1):67-75
pubmed: 9578462
Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):283-94
pubmed: 12663332
BMC Cancer. 2014 May 03;14:310
pubmed: 24885595
J Immunol. 2016 Aug 1;197(3):899-909
pubmed: 27316687
J Ovarian Res. 2017 May 5;10(1):33
pubmed: 28476165
J Immunol. 2014 Sep 1;193(5):2218-29
pubmed: 25070848
J Immunol. 2006 Nov 1;177(9):5968-79
pubmed: 17056521
Inflamm Bowel Dis. 2007 Feb;13(2):200-10
pubmed: 17206679
J Clin Gastroenterol. 2018 Aug;52(7):e53-e62
pubmed: 28723856
Inflamm Bowel Dis. 2005 Jun;11(6):567-75
pubmed: 15905704
Gastroenterology. 2005 Aug;129(2):550-64
pubmed: 16083712
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1964-1973
pubmed: 28442379
J Exp Med. 2017 Sep 4;214(9):2523-2533
pubmed: 28710273
Mediators Inflamm. 2015;2015:964131
pubmed: 25948887
Oncogene. 2018 Aug;37(34):4639-4661
pubmed: 29765155
Am J Physiol. 1997 Dec;273(6):G1341-8
pubmed: 9435560
Cancer Immunol Res. 2018 Dec;6(12):1459-1471
pubmed: 30209062
Scand J Gastroenterol. 2010 Aug;45(7-8):862-71
pubmed: 20367198
Cytokine. 2018 Sep;109:29-51
pubmed: 29903573
Gastroenterology. 2015 Nov;149(6):1564-1574.e3
pubmed: 26170138
Gastroenterology. 2008 Oct;135(4):1228-1237, 1237.e1-2
pubmed: 18760278
Gastroenterology. 2011 Jun;140(7):2019-30
pubmed: 21376048
Gastroenterol Res Pract. 2016;2016:2456179
pubmed: 27034654
Gut. 2006 Dec;55(12):1774-80
pubmed: 16682426
Dig Liver Dis. 2005 Aug;37(8):584-92
pubmed: 15869913
J Neurochem. 2016 Oct;139 Suppl 2:91-114
pubmed: 26525923
Prog Mol Biol Transl Sci. 2017;147:167-195
pubmed: 28413028
Clin Exp Immunol. 1997 Aug;109(2):377-86
pubmed: 9276536
Gastroenterology. 2011 May;140(6):1756-1767
pubmed: 21530742
Dig Dis. 2012;30(3):289-95
pubmed: 22722554
Arthritis Rheum. 2008 Apr;58(4):1001-9
pubmed: 18383392
Inflamm Bowel Dis. 2018 Jan 18;24(2):332-345
pubmed: 29361086